Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 2, 2020
Daily News
October 2, 2020
- Novartis’ Tabrecta Hits Snag in Japan on Hospitals’ CDx Reimbursement Issue
October 2, 2020
- Japanese Nephrology Society Publishes Recommendation on Use of HIF-PH Inhibitors
October 2, 2020
- PMDA to Offer Free Consultations for COVID-19 Vaccines
October 2, 2020
- Maruishi to Discontinue Precedex after Pfizer Pact Expires
October 2, 2020
- UCB Japan Goes Solo on E Keppra Marketing as Otsuka Deal Ends
October 2, 2020
- Fujifilm to Manufacture VLP Therapeutics’ COVID-19 Vaccine
October 2, 2020
- MHLW Bankrolls 3 Projects Aiming to Manufacture Key APIs, Raw Materials in Japan
October 2, 2020
- Ex-MHLW Official Takeyuki Sato Named JGA Director General
October 2, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…